Table 1. The demographic and clinical characteristics of the participants.

Characteristics	GD patients	Active GD	Inactive GD	Healthy controls
Number	40	14	26	30
Age(years)	37.73±12.32	36.86±12.35	38.19±12.52	36.80±10.49
Sex(female/male)	30/10	12/2	18/8	20/10
Disease duration(years)	2.81±1.23	2.61±1.11	2.91±1.29	-
Diffuse goiter n (%)	5(12.5)	5(35.71)	0(0)	-
Ophthalmopathy n (%)	3(7.5)	2(14.29)	1(3.85)	-
TSH (mIU/Ml)	0.03±0.02	0.02±0.02	0.03±0.02	0.34–5.6
FT4 (pmol/L)	22.50±28.17	50.64±31.25	7.34±6.92	10.3–24.5
FT3 (pmol/L)	19.53±17.20	20.93±19.15	18.17±16.40	3.3–6.3
TRAB(IU/mL)	20.64±7.77	23.69±10.08	19.00±5.77	0.11–30
TgAb(IU/mL)	249.83±248.85	354.50±335.63	193.47±169.09	<30
TPO-AB(IU/mL)	392.32±282.56	538.53±293.61	316.29±249.76	<30
Treatment(mg)	Range:50∼150	Range:50∼150	Range:50∼150	-

TSH, thyrotropin; FT4, free thyroxin; FT3, free triiodothyronine; TRAB, thyrotropin receptor antibody; TPOAb, thyroid peroxidase antibody; TgAb, thyroglobulin antibody; Data shown are the case number or median (range). (mg,Propylthiouracil,Methimazole).